Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 (Cadonilimab) in Advanced Solid Tumors
NCT04172454Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Dec 2019
- Primary completion
- Jun 2021
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in solid tumor and melanoma, sponsored by Akeso, Inc. Primary endpoint: Objective Response Rate up to 2 years. Started Dec 2019; status: completed.
02
Drugs
cadonilimab
03
Conditions
solid tumormelanoma
Beyond the preview
Go deeper on NCT04172454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04172454.